Intervention

Wegovy ®

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting2

Common conditions4

Lead sponsors shown3

Clinical trials

3 shown

The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and ObesityNCT06830343 · 2025-02-27

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsNCT07036172 · 2025-01-03

Semaglutide in Patients Undergoing Transcatether Aortic Valve ReplacementNCT07090343 · 2026-04-01

NOT_YET_RECRUITING

Common conditions

Aortic Stenosis1 Heart Failure1 Obesity Control1 Overweight or Obesity1

Leading sponsors

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.1 Leiden University Medical Center1

Trial status mix

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE32

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.